<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01507701</url>
  </required_header>
  <id_info>
    <org_study_id>NorCAPITALps</org_study_id>
    <nct_id>NCT01507701</nct_id>
  </id_info>
  <brief_title>Pilot Study for the NorCAPITAL Trial</brief_title>
  <official_title>Pilot Study for the NorCAPITAL Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study for the NorCAPITAL trial is to investigate the feasibility and
      safety of the drug clonidine in adolescent chronic fatigue syndrome (CFS). Specifically, the
      investigators wanted to assess appropriate dosage in relation to a) plasma concentration
      levels of clonidine, b) orthostatic cardiovascular responses (the pulse and blood pressure
      responses when rising up), and c) reports of possible adverse effects.

      A possible beneficial effect of clonidine in adolescent CFS will be investigated in
      NorCAPITAL, which is a randomized, placebo-controlled, double blind trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration level (Cmax and Co) of clonidine</measure>
    <time_frame>After 14 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Orthostatic cardiovascular responses (head-up tilt test)</measure>
    <time_frame>After 14 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reports of adverse effects</measure>
    <time_frame>Participants will be followed for the duration of treatment period, an expected average of 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration (Cmax) of clonidine</measure>
    <time_frame>First day of treatment, approximately 5 hours after the first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Chronic Fatigue Syndrome</condition>
  <arm_group>
    <arm_group_label>Clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.</description>
    <arm_group_label>Clonidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persisting or constantly relapsing fatigue lasting 3 months or more

          -  Functional disability resulting from fatigue to a degree that prevent normal school
             attendance

          -  Age between 12 and 19 years

        Exclusion Criteria:

          -  Another disease process or current demanding life event that might explain the fatigue

          -  Another chronic disease

          -  Permanent use of drugs

          -  Permanently bed-ridden

          -  Positive pregnancy test

          -  Supine systolic blood pressure (SBP) &lt; 85 mm Hg

          -  Fall in SPB upon standing &gt; 30 mm Hg

          -  Supine HR &lt; 50 beats/min

          -  Abnormal ECG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vegard Bruun Wyller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital Rikshospitalet, Dept. of Pediatrics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital Rikshospitalet, Dept. of Pediatrics</name>
      <address>
        <city>Oslo</city>
        <zip>NO-4950</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2012</study_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Vegard Bruun Wyller</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

